Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.

doi:10.1016/j.jbc.2023.104814

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.

The Journal of biological chemistry - 1 Jun 2023

Hong Xuan, Hsieh Min-Tsang, Tseng Tzu-Yu, Lin Hui-Yi, Chang Hung-Chih, Yau Sir-Theng, Cheng Wei-Chung, Ke Baozhen, Liao Hsiao-Hui, Wu Chih-Ying, Liu An-An, Wu Meei-Maan, Huang Kuo-Yen, Yang Pan-Chyr, Kuo Sheng-Chu, Hung Mien-Chie, Lee Pei-Chih

Abstract excerpt

Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) patients often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop resistance to TKIs. The switch of EGFR downstream signaling from TKI-sensitive to TKI-insensitive is a critical mechanism-driving resistance to TKIs. Identification of potential therapies to target EGFR effectively is a potential strategy to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Lysosomes

Share to Mice

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 37178919
DOI: 10.1016/j.jbc.2023.104814
PMCID: PMC10276293

Provenance

PubMed metadata and Literature Corpus relationships.